Articles related to BUSINESS & POLICY

A video conversation between a senior advisor at ADVI, a physician from Texas Oncology, and the division director of practice health for ASCO discuss the main provisions of the Inflation Reduction Act (IRA) and its implications for oncologists and oncology practices. The panel discusses why practices may have to bear a larger share of the cost of drugs and be ready for utilization cuts by focusing on two important aspects of the IRA: the $2,000 cap on patients’ out-of-pocket expenses and Medicare price negotiation. All three concur that if the act isn’t changed, it might slow down the development of medicines for some indications.

“The perfect storm of lazy MDs, an incompetent ASA and the dramatic taming of the traditionally wild surgical procedures and advances in anesthesia have set up the perfect stage for the aggressive takeover of the specialty by the nursing realm, where it all started in the first space. Today’s MD anesthesiologists have ceded control of the specialty and are rightly a footnote in history—not ‘misunderstood’ at all, as Dr. Sherer would have us believe.”

Mikkael A. Sekeres, MD, currently Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center at the University of Miami, worked on the decision to remove Avastin’s indication for the treatment of HER2-negative metastatic breast cancer in 2008. As a result of the hearing, Dr. Sekeres poses the following question in his most recent book, Drugs and the FDA: Safety, Efficacy, and the Public’s Trust: “Had the FDA made a mistake in initially approving the drug?” Dr. Sekeres discussed with OBR the rise of accelerated approvals, progression-free survival as an endpoint, and the consequences of the Avastin hearing.

The new guidelines have drawn criticism and many or most hospitals are sticking to state guidelines, which generally mandate masking. Megan Ranney, MD, MPH, of Brown University tweeted that CDC’s logic “escapes me,” as it pertains to society’s “most health-vulnerable” people in a setting with a higher-than-average risk of COVID positivity.

In a study of parenteral cancer drug pricing at 61 NCI-designated cancer centers, median price markups on 25 commonly used drugs ranged from approximately 120% to 630% over acquisition cost. The paper’s authors recommend public policy prohibiting excessive markup on parenteral chemotherapies as a means to reduce unnecessary financial burden on patients.

A strongly worded opinion piece in The British Medical Journal argues that evidence-based medicine has been corrupted. Specifically, the editorial piece argues that the pharmaceutical industry’s responsibility to its shareholders means that priority must be given to their hierarchical power structures, product loyalty, and public relations propaganda over scientific integrity.